In this episode of Expose MASH [formerly NASH], our experts will discuss some of the major barriers to screening for MASLD/MASH in the primary care and endocrinology settings. They will identify these barriers and misconceptions that contribute to the low rates of MASLD/MASH diagnosis, and provide their perspectives on how we can best overcome these challenges. This episode is brought to you by Novo Nordisk Inc.

Recent advances in understanding steatotic liver disease have revealed overlapping biological processes that may contribute to non-alcoholic fatty liver disease (NAFLD). Join us in this podcast series where your colleagues will take you on a journey to better understand the cardiometabolic basis for metabolic dysfunction-associated steatohepatitis (MASH), formerly known as non-alcoholic steatohepatitis (NASH), which has long been recognized as “the hepatic manifestation of the metabolic syndrome.” In this series, we will explore MASH, including epidemiology, pathophysiology, comorbidities, patients at risk, and HCP perspectives on the patient journey. This series is tailored specifically for healthcare professionals seeking deeper insights into MASH.

Expose MASH [Formerly NASH] is tailored for healthcare professionals seeking to stay at the forefront of liver disease knowledge. This podcast is sponsored by Novo Nordisk and is intended for U.S. clinicians. This podcast is not to be used as medical advice.